Asthmatx

Sunnyvale, United States Founded: 2003 • Age: 23 yrs Acquired By Boston Scientific
Bronchial thermoplasty devices are developed for adult asthma treatment.
Annual revenue - Latest available
Total funding $50.0M 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 4 Brand Intelligence

About Asthmatx

Asthmatx is a company based in Sunnyvale (United States) founded in 2003 was acquired by Boston Scientific in September 2010. Asthmatx has raised $50 million across 1 funding round from investors including Boston Scientific and Olympus. Asthmatx operates in a competitive market with competitors including Nuvaira, RejuvenAir and D R Burton, among others.

  • Headquarter Sunnyvale, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Asthmatx Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $50 M (USD)

    in 1 rounds

  • Latest Funding Round
    $50 M (USD), Series D

    May 15, 2007

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Boston Scientific

    (Sep 20, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Asthmatx

Asthmatx has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Series D round of $50 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Asthmatx

Asthmatx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Boston Scientific and Olympus.

All
Institutional
Investor Description Founded Year Domain Location
Manufacturer of imaging and surgical products
Locked Locked Locked
Wide range of medical devices
Locked Locked Locked
Premium access

Investor details for Asthmatx

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Asthmatx

Investments
Premium access

Investment portfolio details for Asthmatx

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Asthmatx

Premium access

Detailed financials for Asthmatx

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Asthmatx Comparisons

Asthmatx Primary company
Description
Bronchial thermoplasty devices are developed for adult asthm...
Location
Sunnyvale, United States
Founded Year
2003
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Asthmatx

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Asthmatx

Asthmatx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuvaira, RejuvenAir and D R Burton, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
A catheter-based system for COPD treatment is developed and provided.
Locked Locked Locked
Cryosurgical device for chronic bronchitis and COPD treatment is developed.
Locked Locked Locked
Provides comprehensive products for positive pressure therapy in lung disease patients.
Premium access

Detailed competitors of Asthmatx

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Asthmatx

Premium access

Complete news archive for Asthmatx

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Asthmatx

Asthmatx was founded in 2003 and raised its 1st funding round 4 years after it was founded.

Asthmatx is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.

Asthmatx is a funded company, having raised a total of $50M across 1 funding round to date.

Asthmatx is a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal radiofrequency energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. The Alair Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well-controlled with inhaled corticosteroids and long-acting beta-agonist medicines. Patients are treated in multiple sessions, each targeting a different section of the airways.

Asthmatx's top competitors include Nuvaira, RejuvenAir and D R Burton.

Asthmatx has 2 investors. Key investors include Boston Scientific, and Olympus.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available